Related Experiment Video

Updated: Apr 8, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K

Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment

Karin Larsson1, Per-Johan Jakobsson1

  • 1Department of Medicine, Karolinska Institutet, SE-171 76 Stockholm, Sweden.

Prostaglandins & Other Lipid Mediators
|June 24, 2015
PubMed

Insights

Targeting microsomal prostaglandin E synthase-1 (mPGES-1) may offer a new strategy for cancer prevention. Inhibiting mPGES-1 could reduce tumor progression without the severe side effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs).

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Prostaglandin E2 (PGE2) is a bioactive lipid implicated in the carcinogenesis of common cancers like colon, lung, prostate, and breast cancer.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase (COX) reduce colon cancer incidence but have severe gastrointestinal and cardiovascular side effects.
  • Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the second step in PGE2 biosynthesis, making it a potential therapeutic target.

Purpose of the Study:

  • To investigate the role of mPGES-1 in cancer progression.
  • To evaluate the potential of mPGES-1 inhibition as a cancer chemoprevention strategy.
  • To explore an alternative to NSAIDs with reduced adverse effects.

Main Methods:

  • Genetic deletion of the mPGES-1 enzyme in mouse models of colon cancer.
  • Analysis of tumor progression in genetically modified mice.
  • Comparison of outcomes with traditional NSAID treatments.

Main Results:

  • Genetic deletion of mPGES-1 led to reduced tumor progression in colon cancer mouse models.
  • This suggests that inhibiting mPGES-1 activity can impede cancer development.
  • Potential for a safer chemopreventive approach compared to NSAIDs.

Conclusions:

  • Inhibition of mPGES-1 presents a promising therapeutic strategy for cancer chemoprevention.
  • Targeting mPGES-1 may offer a way to reduce cancer incidence and progression.
  • This approach could avoid the significant side effects associated with long-term NSAID use.
Keywords:
Cancer treatmentMicrosomal prostaglandin E synthase-1Prostaglandin E(2)Targeted therapy

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K